This company has been marked as potentially delisted and may not be actively trading. Ritter Pharmaceuticals (RTTR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RTTR vs. GYRE, DAWN, ABUS, EOLS, KALV, ANAB, COGT, TRVI, SION, and XNCRShould you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), Arbutus Biopharma (ABUS), Evolus (EOLS), KalVista Pharmaceuticals (KALV), AnaptysBio (ANAB), Cogent Biosciences (COGT), Trevi Therapeutics (TRVI), Sionna Therapeutics (SION), and Xencor (XNCR). These companies are all part of the "medical" sector. Ritter Pharmaceuticals vs. Its Competitors Gyre Therapeutics Day One Biopharmaceuticals Arbutus Biopharma Evolus KalVista Pharmaceuticals AnaptysBio Cogent Biosciences Trevi Therapeutics Sionna Therapeutics Xencor Ritter Pharmaceuticals (NASDAQ:RTTR) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings. Which has higher valuation and earnings, RTTR or GYRE? Ritter Pharmaceuticals has higher earnings, but lower revenue than Gyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRitter PharmaceuticalsN/AN/A-$10.13MN/AN/AGyre Therapeutics$100.64M7.86-$92.93M$0.02422.00 Which has more volatility and risk, RTTR or GYRE? Ritter Pharmaceuticals has a beta of -0.43, suggesting that its stock price is 143% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Do analysts rate RTTR or GYRE? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ritter Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor RTTR or GYRE? In the previous week, Gyre Therapeutics had 6 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 6 mentions for Gyre Therapeutics and 0 mentions for Ritter Pharmaceuticals. Gyre Therapeutics' average media sentiment score of 0.62 beat Ritter Pharmaceuticals' score of 0.00 indicating that Gyre Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Ritter Pharmaceuticals Neutral Gyre Therapeutics Positive Is RTTR or GYRE more profitable? Ritter Pharmaceuticals has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -84.57%. Ritter Pharmaceuticals' return on equity of 0.00% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ritter PharmaceuticalsN/A N/A -162.05% Gyre Therapeutics -84.57%-118.43%-71.97% Does the MarketBeat Community prefer RTTR or GYRE? Ritter Pharmaceuticals received 301 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Gyre Therapeutics an outperform vote while only 70.23% of users gave Ritter Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRitter PharmaceuticalsOutperform Votes30270.23% Underperform Votes12829.77% Gyre TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes Do institutionals and insiders believe in RTTR or GYRE? 0.8% of Ritter Pharmaceuticals shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 15.4% of Ritter Pharmaceuticals shares are held by company insiders. Comparatively, 19.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryGyre Therapeutics beats Ritter Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Ritter Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RTTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTTR vs. The Competition Export to ExcelMetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$173.83M$6.84B$5.56B$8.61BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-5.898.7827.1720.06Price / SalesN/A255.64409.72157.10Price / CashN/A65.8538.2534.64Price / Book37.666.557.064.70Net Income-$10.13M$143.93M$3.23B$247.88M Ritter Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTTRRitter PharmaceuticalsN/A$3.77+3.2%N/A+1,725.0%$173.83MN/A-5.897Gap UpGYREGyre Therapeutics0.4452 of 5 stars$7.68-15.3%N/A-19.8%$720.06M$100.64M384.0040News CoverageShort Interest ↓High Trading VolumeDAWNDay One Biopharmaceuticals1.6632 of 5 stars$7.01+9.9%$30.57+336.1%-44.1%$710.55M$161.92M-6.8160Positive NewsABUSArbutus Biopharma2.1708 of 5 stars$3.36flat$5.50+63.7%+13.1%$643.53M$6.40M-7.8190Positive NewsEOLSEvolus4.1075 of 5 stars$9.97+8.5%$23.75+138.2%-13.6%$642.83M$275.46M-10.96170News CoveragePositive NewsInsider TradeGap UpHigh Trading VolumeKALVKalVista Pharmaceuticals3.9421 of 5 stars$12.92+9.5%$24.83+92.2%+18.0%$642.33MN/A-3.55100Positive NewsInsider TradeAnalyst RevisionHigh Trading VolumeANABAnaptysBio1.6761 of 5 stars$21.86-1.7%$40.38+84.7%+1.5%$642.25M$111.87M-3.60100COGTCogent Biosciences2.484 of 5 stars$5.61+3.1%$14.57+159.7%-13.7%$638.73MN/A-2.2680Positive NewsHigh Trading VolumeTRVITrevi Therapeutics3.4522 of 5 stars$6.32-2.9%$18.63+194.7%+157.3%$631.32MN/A-14.3620High Trading VolumeSIONSionna TherapeuticsN/A$13.97+2.0%$38.50+175.6%N/A$616.41MN/A0.0035XNCRXencor4.2013 of 5 stars$8.58+7.3%$29.50+243.8%-55.5%$610.65M$127.23M-2.68280Positive News Related Companies and Tools Related Companies Gyre Therapeutics Competitors Day One Biopharmaceuticals Competitors Arbutus Biopharma Competitors Evolus Competitors KalVista Pharmaceuticals Competitors AnaptysBio Competitors Cogent Biosciences Competitors Trevi Therapeutics Competitors Sionna Therapeutics Competitors Xencor Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTTR) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RTTR Stock Free RTTR Stock Alerts